|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/36 | |
| C07K 14/16 | |||
| C07K 14/745 |
| (11) | Number of the document | 2680875 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12707095.1 |
| Date of filing the European patent application | 2012-03-02 | |
| (97) | Date of publication of the European application | 2014-01-08 |
| (45) | Date of publication and mention of the grant of the patent | 2019-10-23 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2012/053619 |
| Date | 2012-03-02 |
| (87) | Number | WO 2012/117091 |
| Date | 2012-09-07 |
| (30) | Number | Date | Country code |
| 11156682 | 2011-03-02 | EP | |
| 201161449254 P | 2011-03-04 | US |
| (72) |
HILDEN, Ida, DK
PESCHKE, Bernd, DK
BREINHOLT, Jens, DK
KOFOD-HANSEN, Mikael, DK
|
| (73) |
Novo Nordisk Health Care AG,
Thurgauerstrasse 36/38 8050 Zürich,
CH
|
| (54) | COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS |
| COAGULATION FACTOR-TARGETING TO TLT-1 ON ACTIVATED PLATELETS |